Related Experiment Videos
Somatostatin in neuropsychiatric disorders
D R Rubinow1, C L Davis, R M Post
1National Institute of Mental Health, Biological Psychiatry Branch, Bethesda, Maryland.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|January 1, 1988
Summary
Somatostatin, a key brain peptide, shows altered levels in neuropsychiatric disorders. Decreased somatostatin in cerebrospinal fluid may be significant in depression, warranting further research.
Area of Science:
- Neuroscience
- Endocrinology
- Psychiatry
Background:
- Somatostatin is a peptide neurotransmitter widely distributed in the central nervous system.
- Alterations in somatostatin levels are observed in various neuropsychiatric disorders.
- Somatostatin possesses significant neuroregulatory functions.
Purpose of the Study:
- To summarize the central nervous system effects of somatostatin.
- To identify neuropsychiatric disorders associated with altered somatostatin levels.
- To review the evidence for reduced cerebrospinal fluid somatostatin in depression.
Main Methods:
- Literature review of studies on somatostatin's CNS effects.
- Analysis of research linking somatostatin to neuropsychiatric conditions.
- Examination of studies measuring cerebrospinal fluid somatostatin in depression.
Main Results:
- Somatostatin plays a crucial role in neuroregulation.
- Specific neuropsychiatric disorders exhibit changes in somatostatin.
- Evidence suggests a decrease in cerebrospinal fluid somatostatin in depressive states.
Conclusions:
- Somatostatin's central nervous system actions are relevant to neuropsychiatric disorders.
- Cerebrospinal fluid somatostatin levels may serve as a biomarker for depression.
- Further investigation into somatostatin's role in depression is warranted.